Thermo Fisher Scientific

Activities

Categories

• Service
• Technology Supplier

Therapeutic applications

Expertises

Directory of Antibodies, Recombinant proteins and others

• Target selection & validation
• Gene / protein discovery
• bioinformatics design
• Assay development in in-vitro & in-vivo models
• Hit discovery
• Screening & Identification
• Therapeutic libraries
• In-vitro & ex-vivo models
• Immunotherapy lead generation
• Cell activation
• Avidity testing
• Cell-based activation (APCs, AAPCs)
• Bead-base activation
• Antibody-based activation
• Ex-vivo activation (cell transfer)
• Gene modification / Transduction
• Retroviral & lentiviral vectors
• Transposon/transposase
• mRNA electroporation
• CRISPR/Cas9
• Immunotherapy lead optimization
• Proof of concept
• Pharmacology potency
• Exploratory toxicology
• in-vitro & ex-vivo models
• in-vivo models
• Bioproduction
• Batches production type
• Mammalian
• Insect
• Yeast
• Bacterial
• GLP compliance
• GMP compliance
• Pilot Batches
• Tests
• Optimization
• Scale-Up process
• Process optimization & validation
• Volume
• Preclinical / Tox
• Low volume (< 200 L)
• High volume (200 – 2000 L)
• Very high volume (> 2000 L)
• Commercial
• USP (Scale-Up)
• Cell expansion
• Inoculation
• Low volume containers to Bioreactors
• DSP (Recovery)
• Harvest
• Filtration
• Purification
• Batch release
• Logistic
• Cell cryopreservation
• Controlled-rated freezer
• thaw
• Quality assurance, quality control & analytical process
• Stability Assessment
• pH
• Cell line analytical development
• Host cell proteins
• Bioproduction analytical test
• Characterization
• Batch release test
• Quality control test support
• Clinical trials
• Phase I
• Phase II
• Phase III
• Phase IV
• Clinical biomarkers
• Predictive biomarkers
• Treatment efficacy
• Population stratification
• Risk/benefit profile
• Disease progression / follow-up
• Safety
• PK/PD features
• Surrogate markers
• Disease progression monitoring
• Post-market surveillance
• Post-Market Surveillance
Cell Therapy Directory

• Target cell isolation
• iPS reprogramming
• Differentiated Cell
• Production Cell
• Cell modification
• Direct reprogramming
• Cell Activation
• Ex Vivo & In Vivo Strategy
• Ex Vivo & In Vivo Strategy
• CMC/analytical quality assessment, quality control
• Cleaning
• Sterility
• Contaminants detection
• Safety for gene-edited cells
• translocation
• anti-nuclease response
• cytokine-independent growth
• Bioproduction engineering
• Cell Expansion
• Stirred tank Bioreactor
• Wave bioreactor
• Cell factory
• Microcarrier-based culture
• Organoids culture
• Capsules culture
• Scale-Up
• Process optimization
• Automated manufacturing
• On-line monitoring
• Automated high throughput microbioreactor system
• Non-GMP expansion
• GMP expansion
• Other
• Purification/Extraction
• Filtration / microfiltration / ultrafiltration
• Centrifugation
• Chromatography
• CGMP
• Bioproduction modeling
• Metabolic / Kinetic modeling
• Control / command
• Global optimization
• Economic analyses
• Artificial Intelligence tools
• Formulation
• Conditioning
• Storage
• Delivery
• Transport
• Supply chain logistics
• Tracking process
• Monitoring logistics
Gene and CAR-T cell therapy Directory

• Target Identification
• Assay development in in-vitro & in-vivo models
• Gene Cloning
• Gene augmentation
• Gene inhibition
• Killing Gene
• KI / KO
• (Gene) engineering
• CRISPR activation
• CRISPR interference
• TALEN
• Gene Delivery System
• Lentivirus
• Other Retrovirus
• Adeno-Associated Virus (AAV)
• Adenovirus (ADV)
• Electroporation
• Lipid chemical methods
• CAR Construction
• T-cell activation/transduction
• Bioproduction/CMC/Analytical Quality Assessment, Quality Control
• Bioproduction
• Scale-Up
• Automated manufacturing
• Supply chain logistics
• Non-GMP pilot batch
• GMP batch
• Cleaning
• CGMP
• Sterility
• Quality control
• Contaminants detection
• Safety for gene-edited cells
• Translocation
• anti-nuclease response
• cytokine-independent growth
Prophylactic Vaccines Directory

• Antigen identification, selection, optimization, and validation
• Antigen optimization:
• Generation of mutants
• Early purification
• Pathogen-host knowledge
• Pathogen genetics and mechanism of action
• Biomolecular analysis
• In-vitro and in-vivo models
• Antigen-protective immune-response profile
• Humoral response characterization:
• Antibody dosage
• Vaccine: antigen format platforms
• Recombinant protein expression
• Bacterial
• Cell
• Fungi
• Synthetic Peptides or oligomers
• Viral vector encoding target antigen
• CMC
• GMP compliance
• Cell Culture / Fermentation
• media formulation and supply
• Bioreactor conditions (cell in suspension, adherent cell player)
• Ability to work in BSL2 conditions
• Cell expansion
• Single use technology (SUS)
• Stirred tank reactors
• Gene modification / Transduction
• Molecular biology
• Expression systems
• Clinical trials
• Phase I
• Phase II (human challenge trials)
• Phase III (large population pending pathogen prevalence)
• Immune monitoring
• Data management
• Bioproduction GMP
• Vaccine platform type
• Recombinant protein expression
• Synthetic Peptides or oligomers
• Viral vector encoding target antigen
• DNA plasmid vaccine
• mRNA vaccine
• Pilot Batches scale
• Process development & optimization
• Scale-Up & Validation
• Comparability characterization protocol
• Manufacturing Volume
• Small volume (< 100 L) adjusted to phase I/II needs: specify volume
• Large volume (100 – 1000 L) adapted for phase III needs
• Final scale up volume (> 1000 L) and validation for manufacturing
• Commercial supply during life cycle management
• USP (Scale-Up)
• Post-market surveillance
• Clinical Trial phase IV
• Immune monitoring